IONIS-PKKRx
/ Ionis
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 18, 2024
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
(PubMed, Expert Opin Investig Drugs)
- "ATN-249 is an oral drug that has shown promising results in preclinical and Phase I studies, and good tolerability in the prophylactic treatment of attacks. KVD900 is also an oral agent developed for the on-demand treatment of HAE attacks...The third drug, IONIS-PKKRx, is an antisense oligonucleotide targeting plasma prekallikrein mRNA...STAR-0215 is a long acting anti-activated kallikrein monoclonal antibody...Lastly, NTLA-2002 is an investigational gene-editing therapy. The targeted treatment of the dysregulated kinin-kallikrein system with specific inhibitors is promising for the prevention of angioedema attacks. Ongoing phase III studies will provide further insight into the efficacy and long-term safety of these novel therapies, potentially expanding treatment options for HAE treatment."
Journal • Preclinical • Review • Cardiovascular • Complement-mediated Rare Disorders • Genetic Disorders • Hereditary Angioedema
February 05, 2020
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine
(clinicaltrials.gov)
- P2; N=30; Completed; Sponsor: Smith, Timothy R., M.D.; N=43 ➔ 30
Clinical • Enrollment change
May 01, 2019
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine
(clinicaltrials.gov)
- P2; N=43; Completed; Sponsor: Smith, Timothy R., M.D.; Active, not recruiting ➔ Completed
Clinical • Trial completion
April 04, 2019
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine
(clinicaltrials.gov)
- P2; N=43; Active, not recruiting; Sponsor: Smith, Timothy R., M.D.; Trial completion date: Dec 2018 ➔ Jun 2019; Trial primary completion date: Dec 2018 ➔ Jun 2019
Clinical • Trial completion date • Trial primary completion date
1 to 4
Of
4
Go to page
1